Drug Approval | August 28, 2023
Briefs: Granules India
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
This product will be manufactured at Lupin's Pithampur facility in India
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
Zinc Sulfate Injection is indicated in adult and paediatric patients as a source of zinc for parenteral nutrition
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
The company has entered into a three-year Deferred Prosecution Agreement
Subscribe To Our Newsletter & Stay Updated
